Limb-Girdle Muscular Dystrophy Type 1 – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Limb-Girdle Muscular Dystrophy Type 1 (LGMD1A, LGMD1B, LGMD1C, & Others (LGMD1D-H)) includes forms of the disorder that have an inheritance pattern called autosomal dominant. Majorly the LGMD1B comprises more than 65% of the total Limb-girdle muscular dystrophy type 1, followed by LGMD1C, LGMD1A, & Others type. The autosomal dominant forms of LGMD are less common than the autosomal recessive forms and appear later in life. In many cases, autosomal dominant LGMD progresses more slowly than autosomal recessive LGMD and has variable symptoms, even among members of the same family. Each gene mutation can cause a wide range of symptoms. LGMD1A can appear at any age, from adolescence to adulthood. This type of LGMD is distinguished by proximal muscle weakness, which is sometimes accompanied by slurred speech (dysarthria) and an abnormally tight Achilles tendon. LGMD1B causes proximal muscle weakness that gradually worsens. Affected individuals may also experience calf muscle hypertrophy and mild elbow or Achilles tendon contractures. LGMD1C is characterized by cramping muscle pain after exercise, mild to moderate proximal muscle weakness, and overgrowth of the calf muscle. LGMD1D-H short form is characterized by progressive muscle weakness that affects the hip-girdle area before spreading to the limb-girdle area.

·       The incidence of Limb-girdle muscular dystrophy type 1 varies from 3 to 4 cases per million population in the USA.

 

Thelansis’s “Limb-Girdle Muscular Dystrophy Type 1 Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Limb-Girdle Muscular Dystrophy Type 1 treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Limb-Girdle Muscular Dystrophy Type 1 across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Limb-Girdle Muscular Dystrophy Type 1 Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Limb-Girdle Muscular Dystrophy Type 1 – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Limb-Girdle Muscular Dystrophy Type 1, Limb-Girdle Muscular Dystrophy Type 1 market outlook, Limb-Girdle Muscular Dystrophy Type 1 competitive landscape, Limb-Girdle Muscular Dystrophy Type 1 market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)